111 related articles for article (PubMed ID: 9586287)
1. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients.
Patiño-García A; Sierrasesúmaga L
Cancer Genet Cytogenet; 1997 Oct; 98(1):50-5. PubMed ID: 9309118
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
6. Mutation spectrum of p53 gene in highly malignant human osteosarcomas.
Radig K; Schneider-Stock R; Oda Y; Neumann W; Mittler U; Roessner A
Gen Diagn Pathol; 1996 Jun; 142(1):25-32. PubMed ID: 8793483
[TBL] [Abstract][Full Text] [Related]
7. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53.
Seike M; Gemma A; Hosoya Y; Hemmi S; Taniguchi Y; Fukuda Y; Yamanaka N; Kudoh S
Clin Cancer Res; 2000 Nov; 6(11):4307-13. PubMed ID: 11106248
[TBL] [Abstract][Full Text] [Related]
8. Studies of the RB1 gene and the p53 gene in human osteosarcomas.
Scholz RB; Kabisch H; Weber B; Röser K; Delling G; Winkler K
Pediatr Hematol Oncol; 1992; 9(2):125-37. PubMed ID: 1524989
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
10. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.
Pasic I; Shlien A; Durbin AD; Stavropoulos DJ; Baskin B; Ray PN; Novokmet A; Malkin D
Cancer Res; 2010 Jan; 70(1):160-71. PubMed ID: 20048075
[TBL] [Abstract][Full Text] [Related]
11. Genetic analyses for predictors of radiation response in glioblastoma.
Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
[TBL] [Abstract][Full Text] [Related]
12. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
13. P53 gene abnormalities in osteosarcoma.
Guo W; Wang X; Feng C
Chin Med J (Engl); 1996 Oct; 109(10):752-5. PubMed ID: 9275350
[TBL] [Abstract][Full Text] [Related]
14. p21WAF1 mutation is not a predominant alteration in pediatric bone tumors.
Patiño-García A; Sotillo-Piñeiro E; Sierrasesúmaga-Ariznabarreta L
Pediatr Res; 1998 Mar; 43(3):393-5. PubMed ID: 9580228
[TBL] [Abstract][Full Text] [Related]
15. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
16. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
[TBL] [Abstract][Full Text] [Related]
17. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India.
Munirajan AK; Kannan K; Bhuvarahamurthy V; Ishida I; Fujinaga K; Tsuchida N; Shanmugam G
Gynecol Oncol; 1998 Jun; 69(3):205-9. PubMed ID: 9648588
[TBL] [Abstract][Full Text] [Related]
18. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
19. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
20. The role of TP53 in breast cancer development.
Eeles RA; Bartkova J; Lane DP; Bartek J
Cancer Surv; 1993; 18():57-75. PubMed ID: 8013000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
